Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Amasten on its offer for SSM
Mandate

Vinge advises Amasten on its offer for SSM

October 16, 2020 Capital Markets and Public M&A EU, Competition and Regulatory Banking and Finance Real Estate and Construction Corporate Tax

Vinge advises Amasten Fastighets AB (publ) in connection with its public offer to the shareholders of SSM Holding AB (publ) (“SSM”)

The offer consideration consists of shares in Amasten, corresponding to a value of approximately SEK 400 million. Amasten is a property company that manages, develops and builds. The property portfolio consists of 92 percent housing, whereby the remaining area consists of office, retail, industrial and community premises. SSM produces smart, affordable homes with attractive shared spaces close to public transport and the city centre for its target group – tomorrow’s urbanites.

Vinge’s team consists of Jesper Schönbeck, Rikard Lindahl, Malte St Cyr Ohm, Boris Kotur, Clara Sohlberg, Lisa Malmborg and Emil Lindwall (Capital Markets and Public M&A), Johan Wahlbom and Joel Kokko (EU, Competition and Regulatory), Pauline Lagerstrand and Felix Möller (Banking and Finance), Henrik Wastenson (Corporate Tax) as well as Kristofer Larson (Real Estate).


Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026